Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1215-1222

  Tomcik, Michal ^a,b   Zerr, Pawel ^a   Pitkowski, Jana ^a   Palumbo Zerr, Katrin ^a   Avouac, Jérôme ^a,c   Distler, Oliver ^d   Becvar, Radim ^b   Senolt, Ladislav ^b   Schett, Georg ^a   Distler, Jörg H ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUT COCHIN   (France)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALVESPIMYCIN; BLEOMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 BETA; HYDROXYPROLINE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL NUCLEUS; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MYOFIBROBLAST; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; UPREGULATION; WESTERN BLOTTING;

FIBROBLASTS; SYSTEMIC SCLEROSIS; TREATMENT;

ADULT; AGED; ANIMALS; BENZOQUINONES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FIBROSIS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84899975158     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-203095     Document Type: Article

References (43)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360: 1989-2003.
2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117: 557-67. (Pubitemid 46348510)
3. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003;48: 1964-78. (Pubitemid 36828692)
4. Whitfield ML, Finlay DR, Murray JI, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100: 12319-24. (Pubitemid 37271558)
5. Sonnylal S, Denton CP, Zheng B, et al. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007;56: 334-44. (Pubitemid 46106207)
6. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367: 1683-91. (Pubitemid 43728250)
7. Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996;381: 571-9.
8. Buchner J. Supervising the fold: functional principles of molecular chaperones. FASEB J 1996;10: 10-19. (Pubitemid 26035501)
9. Zügel U, Kaufmann SH. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev 1999;12: 19-39. (Pubitemid 29055952)
10. De Nagel DC, Pierce SK. Heat shock proteins implicated in antigen processing and presentation. Semin Immunol 1991;3: 65-71.
11. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002;2: 185-94. (Pubitemid 37328765)
12. Nardai G, Végh EM, Prohászka Z, et al. Chaperone-related immune dysfunction: an emergent property of distorted chaperone networks. Trends Immunol 2006;27: 74-9. (Pubitemid 43221973)
13. Wrighton KH, Lin X, Feng XH. Critical regulation of TGFbeta signaling by Hsp90. Proc Natl Acad Sci USA 2008;105: 9244-9.
14. Koga F, Xu W, Karpova TS, et al. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci USA 2006;103: 11318-22. (Pubitemid 44156515)
15. Skhirtladze C, Distler O, Dees C, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008;58: 1475-84. (Pubitemid 351705937)
16. Beyer C, Distler JH. Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease. Biochim Biophys Acta 2013;1832: 897-904.
17. Soga S, Akinaga S, Shiotsu Y. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des 2013;19: 366-76.
18. Nahleh Z, Tfayli A, Najm A, et al. Heat shock proteins in cancer: targeting the 'chaperones'. Future Med Chem 2012;4: 927-35.
19. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15: 202-5. (Pubitemid 18073738)
20. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011;208: 961-72.
21. Distler JH, Jüngel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56: 311-22. (Pubitemid 46106205)
22. Lin NY, Beyer C, Gießl A, et al. Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann Rheum Dis 2013;72: 761-8.
23. Schaffner W, Weissmann C. A rapid, sensitive, and specific method for the determination of protein in dilute solution. Anal Biochem 1973;56: 502-14.
24. Krämer M, Dees C, Huang J, et al. Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis 2013;72: 614-20.
25. Palumbo K, Zerr P, Tomcik M, et al. The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011;70: 1320-6.
26. Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun 2012;3:735.
27. Avouac J, Palumbo K, Tomcik M, et al. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum 2012;64: 1642-52.
28. Dees C, Zerr P, Tomcik M, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum 2011;63: 1396-404.
29. Beyer C, Schramm A, Akhmetshina A, et al. β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 2012;71: 761-7.
30. Beyer C, Reich N, Schindler SC, et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012;71: 1019-26.
31. Zerr P, Palumbo-Zerr K, Distler A, et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood 2012;120: 2909-17.
32. Akhmetshina A, Dees C, Pileckyte M, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008;22: 2214-22. (Pubitemid 351948641)
33. Beyer C, Schett G, Distler O, et al. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010;62: 2831-44.
34. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60: 219-24.
35. Haupt A, Joberty G, Bantscheff M, et al. Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics. BMC Cancer 2012;12:38.
36. Weigert O, Lane AA, Bird L, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012;209: 259-73.
37. Reich N, Tomcik M, Zerr P, et al. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis 2012;71: 737-45.
38. Yamamoto T, Takagawa S, Katayama I, et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999;112: 456-62. (Pubitemid 29171935)
39. Green MC, Sweet HO, Bunker LE. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976;82: 493-512.
40. Saito E, Fujimoto M, Hasegawa M, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002;109: 1453-62. (Pubitemid 34596171)
41. Allegra A, Sant'antonio E, Penna G, et al. Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors. Eur J Haematol. 2011;86: 93-110.
42. Sidera K, Patsavoudi E. HSP90 Inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov 2013. [Epub ahead of print]
43. Kim YS, Alarcon SV, Lee S, et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009;9: 1479-92.